Investing In Patents - Conclusion
BlueIron's Patent Myth Podcast
How BlueIron uses the techniques in this book for investing in startups.
info_outline
Investing In Patents - Chapter 4 - Due Diligence on Patents
BlueIron's Patent Myth Podcast
Assignments and provenance
info_outline
Investing In Patents - Chapter 3 - Managing the Process
BlueIron's Patent Myth Podcast
Managing the patent process, from picking the right invention to getting the patent through the examination process.
info_outline
Investing In Patents - Chapter 2 - How Startups Use Patents
BlueIron's Patent Myth Podcast
Getting acquired
info_outline
Investing In Patents - Chapter 1 - The Business Case for Patents
BlueIron's Patent Myth Podcast
Making the Business Case for Patents
info_outline
Investing In Patents - About this Book
BlueIron's Patent Myth Podcast
Russ Krajec reads his book "Investing In Patents" available on Amazon.
info_outline
Webinar - IP Triage - How to manage your IP portfolio
BlueIron's Patent Myth Podcast
Webinar from 9 Apr 2020.
info_outline
Myth 13 - The Examiner Is Out To Get You
BlueIron's Patent Myth Podcast
Patent examiners are widely maligned by applicants and patent attorneys, but they are actually the most underutilized resources that make sure you get good patent assets.
info_outline
Myth #12: Patent Searches
BlueIron's Patent Myth Podcast
Patent searches can be *harmful* or helpful.
info_outline
Myth #11: NDAs and PIIA
BlueIron's Patent Myth Podcast
Non Disclosure Agreements and Proprietary Information and Inventions Agreements are far more important than people realize - especially for startup companies.
info_outline
Customer feedback is essential to know if a patent is worth the expense - but some people think their idea will be "stolen" if they talk to customers.
What should they do?
Two answers:
One, if you need to tell people about your invention when doing customer discover, you are doing it wrong.
Two, there is almost 100% certainty that you will change your product, marketing message, customer pain point, solution, etc. as the company goes through the product-market fit stage, so why bother patenting something we know will change?
When we finance patents, we are very conscious of the one-year grace period in the US, and we would rather wait to have data to support an investment, that to plow money into an asset that is likely to be bad.
The best patents are yet to come.